C3 GLOMERULOPATHY
Clinical trials for C3 GLOMERULOPATHY explained in plain language.
Never miss a new study
Get alerted when new C3 GLOMERULOPATHY trials appear
Sign up with your email to follow new studies for C3 GLOMERULOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare kidney disease: experimental drug NM8074 enters human trials
Disease control Not yet recruitingThis early-phase trial tests a new drug called NM8074 in 18 adults with C3 Glomerulopathy (C3G), a rare kidney disease. The drug is given by IV over several weeks to see if it is safe and can reduce protein in the urine, a sign of kidney damage. Researchers will also check how th…
Matched conditions: C3 GLOMERULOPATHY
Phase: PHASE1, PHASE2 • Sponsor: NovelMed Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New study to map Real-World use of iptacopan in rare kidney disease
Knowledge-focused Not yet recruitingThis study looks back at medical records of about 83 adults with C3 glomerulopathy (C3G), a rare kidney disease, who are taking the drug iptacopan. Researchers will describe patients' health history, lab results, and how their disease changes over a year of treatment. The goal is…
Matched conditions: C3 GLOMERULOPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC